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Abstract: Etravirine is a second-generation non-nucleoside reverse transcriptase inhibitor 
(NNRTI) with the advantages of in vitro potency against many strains of virus resistant to 
efavirenz and nevirapine, as well as a higher genetic barrier to resistance. Etravirine is indicated 
for use in treatment-experienced patients, and the approved dose in adults is 200 mg twice 
daily. Etravirine should be administered after a meal as bioavailability is significantly reduced 
when taken in the fasting state. Etravirine is a substrate of CYP3A4, CYP2C9, CYP2C19, and 
uridine diphosphate glucuronyltransferase, and induces CYP3A4, weakly inhibits CYP2C9 
and moderately inhibits CYP2C19. Etravirine may be coadministered with nucleoside/tide 
reverse transcriptase inhibitors, raltegravir and boosted darunavir, lopinavir, and saquinavir 
without dosage adjustment. Etravirine should not be given with other NNRTIs, unboosted 
protease inhibitors, and atazanavir/ritonavir, tipranavir/ritonavir, and fosamprenavir/ritonavir 
due to unfavorable drug interactions. In randomized, controlled trials, twice daily etravirine 
combined with darunavir/ritonavir plus optimized background therapy demonstrated better 
efficacy compared to darunavir/ritonavir plus optimized background therapy alone in treatment-
experienced populations out to 96 weeks follow-up. The main etravirine-associated toxicity 
is mild to moderate self-limiting rash, although severe and sometimes fatal hypersensitivity 
reactions have been reported. Etravirine offers a potent sequencing option after the development 
of resistance to first-line NNRTIs, and is a welcome addition to this established drug class.
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Introduction
Between 1996 and 1998, 3 non-nucleoside reverse transcriptase inhibitors (NNRTIs), 
nevirapine (NVP), delavirdine (DLV) and efavirenz (EFV) were approved for the treatment 
of HIV-1 infection. Delavirdine quickly fell out of favor due to multiple issues, including 
concerns of viral potency, toxicity, high pill burden of 12 pills daily and inconvenient 
3 times daily dosing schedule, and is not recommended as part of an initial regimen.1
Efavirenz and nevirapine share characteristics of viral potency and long plasma 
half-lives. Efavirenz is available in a fixed-dose combination with tenofovir and 
emtricitabine, which allows for once daily administration of combination antiretroviral 
therapy in a single tablet. In the developing world, NVP is commonly co-formulated 
with stavudine and lamivudine in generic formulations; nevirapine is also an important 
component of abbreviated protocols to prevent mother-to-child transmission of HIV 
infection. Advantages to initiating treatment with an NNRTI-based regimen rather 
than a protease-inhibitor based regimen include lower pill burden and more convenient 
dosing, improved gastrointestinal tolerability, fewer metabolic side effects, avoidance Therapeutics and Clinical Risk Management 2010:6 50
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of potentially dangerous inhibitory drug interactions, and 
lower cost. Since 1998, EFV has been the preferred NNRTI 
of  choice, with NVP classified an alternative agent in this 
class.1–3
Disadvantages of first generation NNRTIs include 
low genetic barrier to resistance4 and prevalence of 
NNRTI-resistant HIV in treatment-naïve patients. A single 
point mutation in the reverse transcriptase gene at the K103N 
position confers marked reduction in drug susceptibility with 
several hundred-fold increases in IC50 or IC90 and pan-class 
resistance.5,6 Of further concern is that NNRTI-resistant 
strains may be transmitted. It is estimated that approximately 
7% of new HIV-infections in the United States involve 
NNRTI-resistant strains.7
Efavirenz is associated with central nervous system 
effects, and is a Category D teratogen. Exposure during the 
first trimester has been associated with neural tube defects 
in newborns, and thus EFV should be avoided in pregnant 
women and in women with high pregnancy potential.6 
Nevirapine is associated with hepatotoxicity and should be 
avoided in patients with high CD4 counts, as well as in those 
with pre-existing mild to moderate hepatic dysfunction.5
Etravirine is the first next-generation NNRTI to come 
to market which aims to overcome some of the negative 
aspects associated with EFV and NVP. Etravirine has 
demonstrated activity against some strains of virus resistant 
to other NNRTIs,8 and is approved for use in treatment-
experienced adult patients. It is not approved for initial 
therapy in previously antiretroviral-naïve individuals, and 
should not be given with NRTIs only when used after an 
earlier NNRTI-based regimen has failed.9 In this paper, 
the most recent efficacy and safety data on etravirine in 
both treatment-naïve and experienced patients will be 
discussed. In addition, data on the use of etravirine in 
special populations will be considered, and pharmacology 
and pharmacokinetics with associated clinical implications 
will be reviewed.
Pharmacology
Etravirine, formerly known as TMC-125 and marketed under 
the trade name Intelence®, is a di-arylpyrimidine analogue 
that binds directly to reverse transcriptase and inhibits 
replication of HIV-1 by causing a disruption of the enzyme’s 
catalytic site. The inherent molecular flexibility of etravirine 
relative to older NNRTIs allows the compound to retain its 
binding affinity to the reverse transcriptase in spite of the 
binding site changes induced by the presence of common 
NNRTI resistance mutations.10
Anti-HIV activity
In vitro against wild-type HIV-1 strains, etravirine inhibits 50% 
of viral replication at a median concentration (EC50) of 0.9 to 
5.5 nmol/L (ie, 0.4 to 2.4 ng/mL) in acutely infected T-cell 
lines. Etravirine demonstrates in vitro activity against a range 
of HIV-1 groups and subgroups, including group M, subtypes 
A, B, C, D, E, F, and G with EC50 of 0.29 to 1.65 nmol/L. 
Etravirine demonstrates moderate activity against group O 
virus with EC50 values of 11.5 to 21.7 nmol/L.9 Etravirine 
does not have activity against HIV-2.8
Etravirine has in vitro activity against a range of 
NNRTI-resistant HIV-1 strains. In a panel of viruses with 
single or double mutations associated with NNRTI resistance, 
18 of 25 strains were susceptible to etravirine with EC50 values 
of 5 nmol/L and fold-change of less than 4 versus wild-
type. Three viral strains, Y181I, F227C and L101I/K103N 
demonstrated significant in vitro resistance to etravirine with 
EC50 values greater than 10 nmol/L and fold change 10.8
Etravirine is synergistic with zidovudine, and has 
additive anti-HIV effects with other antiretrovirals, including 
nucleoside reverse transcriptase inhibitors, NNRTIs and 
protease inhibitors.8
Pharmacokinetics
Etravirine is available as 100 mg tablets. The recommended 
dose in adults is 200 mg twice daily following a meal. The 
safety and efficacy of etravirine have not been established 
in pediatric patients, and hence is not recommended for use 
in patients under 18 years of age.9
Etravirine is highly protein bound (99.9% in vitro) to 
albumin and alpha-1-acid glycoprotein, and has an apparent 
volume of distribution of 422 L. Absorption of etravirine 
is dependent on food. When administered in a fasted state, 
the etravirine AUC is reduced by 51% compared to when 
administered with a standard breakfast. When given with 
either a light breakfast, an enhanced fiber breakfast or a 
high fat breakfast containing 70 g fat, the etravirine AUC 
was decreased 20%, decreased 25% and increased 9%, 
respectively compared to a standard breakfast. These latter 
differences are not considered clinically relevant.11 Therefore, 
etravirine should be administered following a meal 
for optimal absorption.
In healthy subjects, single-dose etravirine 100 mg was 
administered in the presence of steady-state ranitidine 
150 mg twice daily or omeprazole 40 mg daily. In the 
presence of ranitidine, etravirine AUC and Cmax were 86% 
and 94% compared to etravirine alone, and in the presence 
of omeprazole, etravirine AUC and Cmax were 141% and Therapeutics and Clinical Risk Management 2010:6 51
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117% compared to etravirine alone. Therefore, etravirine 
may be coadministered with H2-antagonists and proton-pump 
inhibitors without dose adjustments.12
Etravirine exhibits dose-proportional kinetics in healthy 
volunteer studies. Time to maximum concentration is 
2.5 to 4 hours post-dose, and the mean terminal half-life 
is 41 hours.9 The same daily dose of etravirine results in 
similar daily exposure whether given in a once or twice daily 
regimen.13 Population pharmacokinetic data from the two 
DUET trials yielded mean etravirine AUC12 h of 5506 ng⋅h/mL 
and Cmax of 393 ng/mL. Interpatient variability of 60% and 
intrapatient variability of 40% were observed. There was 
no significant difference in etravirine exposures based on 
race (blacks, Caucasians, Asians) and gender.14 There was 
a trend for higher etravirine levels with increased age, and 
higher etravirine concentrations were noted with decreasing 
weight. Patients coinfected with HIV and hepatitis C had 
higher etravirine exposures, with a mean 1.35-fold increase 
in AUC compared to non-coinfected subjects.14
The pharmacokinetics of etravirine 200 mg bid were 
assessed in 16 HIV negative subjects with mild to moderate 
hepatic impairment, and compared to 16 healthy matched 
controls.15 No significant effect on etravirine kinetics 
was observed in patients with mild hepatic impairment 
(Child–Pugh A). Patients with moderate hepatic impairment 
(Child–Pugh B) had similar Cmin and AUC12 h levels but 
significantly lower Cmax levels compared to healthy controls 
(Day 1: 0.63; 95% CI 0.47 to 0.85. Day 8: 0.72; 95% CI 0.54 
to 0.96). Therefore, etravirine dose adjustment is not required 
in mild to moderate hepatic impairment.15
In a case report of  a woman with severe hepatic dysfunction 
(decompensated liver cirrhosis) who received standard doses 
of tenofovir, etravirine, and darunavir/ritonavir, etravirine 
levels were measured after 8 months of therapy with a virus 
load  50 copies/mL. The etravirine level was 3257 ng/mL, 
approximately 60 times higher than expected concentrations 
with standard etravirine dosing. Etravirine was discontinued, 
and levels measured 2 and 5 weeks later were 931 ng/mL and 
100 ng/mL, respectively. Estimated half-life was calculated 
to be 237 hours. The patient did not experience any clinical 
adverse events.16 Because etravirine had not been well studied 
in this population, caution is advised when using etravirine 
in persons with severe hepatic dysfunction.
Antiretroviral pharmacokinetics were studied in a 
49-year old HIV-positive man virologically suppressed 
on darunavir/ritonavir 600/100 mg twice daily, etravirine 
200 mg twice daily and raltegravir 400 mg twice daily while 
undergoing hemodialysis three times weekly. The morning 
dose of the antiretrovirals was taken after completion of 
the 4-hour morning hemodialysis session. After dialysis, 
darunavir, etravirine, raltegravir and ritonavir concentrations 
were decreased by 57%, 29%, 82% and 60%, respectively 
compared to predialysis levels. A supplemental dose of 
600 mg darunavir administered prior to the hemodialysis 
session was successful in restoring darunavir concentrations 
approximately equal to expected levels, while administration 
of a supplemental dose of raltegravir 400 mg was not, likely 
due to wide intra- and inter-patient variability. Dose supple-
mentation of etravirine was not deemed necessary given the 
relatively low amount removed during hemodialysis. After 1 
year of therapy, the patient maintained viral suppression.17
Etravirine is classified as a Pregnancy Category B agent.9 
Data from well-controlled clinical and pharmacokinetic studies 
in pregnant women are lacking. In rat and rabbit embryo-
fetal studies involving etravirine doses equivalent to 400 mg 
daily in humans, no adverse fetal effects were observed.18 
Etravirine has been used successfully in combination with 
boosted darunavir, enfuvirtide and tenofovir/emtricitabine 
in a pregnant woman with high-level, multiclass resistance. 
Antiretroviral therapy was started at 25 weeks gestation, 
full viral suppression was achieved four weeks later with 
therapeutic maternal plasma levels of darunavir, etravirine, 
and enfuvirtide. Healthy twin babies were born at 34 weeks 
gestation, and significant cord blood levels of darunavir, 
etravirine and ritonavir were measured while enfuvirtide 
concentrations were undetectable. At 4 months of age, both 
babies had negative HIV-1 DNA polymerase tests.19
Efficacy
The antiretroviral efficacy of etravirine has been assessed 
in various Phase IIa and IIb studies in both treatment naïve 
and treatment experienced HIV-infected subjects. In an early 
exploratory phase II study, etravirine demonstrated suboptimal 
virologic suppression compared to a protease-inhibitor (PI) 
regimen in PI-naïve subjects with NNRTI resistance. The 
poorer efficacy in the etravirine arm was thought to be due to 
a combination of high degree of baseline NRTI resistance and 
low bioavailability of the older etravirine formulation used.20 
A newer formulation of etravirine has since been approved, 
and was used in larger phase III studies.
A small study of darunavir/ritonavir and etravirine in 
treatment-experienced patients showed no detrimental 
pharmacokinetic interaction and a high rate of virologic 
success, with 9 of 10 subjects at 24 weeks achieving HIV 
RNA suppression to 40 copies/mL and median CD4 
increase of 113 cells/mm3.21 These results consequently Therapeutics and Clinical Risk Management 2010:6 52
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sparked interest and recruitment for DUET-122 and DUET-2,23 
2 ongoing, large-scale, identically designed, randomized, 
double-blind, placebo-controlled phase III studies. DUET-1 
included 612 subjects from South America, Mexico, France, 
Thailand and USA, while DUET-2 included 591 subjects 
from Australia, Canada, Europe, UK and USA.
Patients were eligible if they had been on stable antiretroviral 
therapy for at least 8 weeks with a viral load 5000 copies/mL 
at screening, and at least one NNRTI resistance mutation 
and three or more primary PI resistance mutations. Subjects 
were randomized to receive either etravirine 200 mg twice 
daily or placebo, plus darunavir 600 mg/ritonavir 100 mg 
twice daily and optimized NRTIs with or without enfuvirtide. 
At baseline, patients in both studies had been infected with 
HIV for a median of 14 years, with a median CD4 count of 
105 cells/mm3 and 4.8 log10 RNA, and 59% had a Center 
for Disease Control and Prevention (CDC) C classification. 
36% of efavirenz patients and 38% of placebo subjects 
had an entry viral load 100,000 copies/mL, and 36% and 
35% in the etravirine and placebo arms respectively had a 
CD4 count 50 cells/mm3. Patients had been treated with 
an average of 12 antiretrovirals and demonstrated exten-
sive HIV resistance, with 36% to 43% having at least 3 
NNRTI-associated mutations, over 90% with 4 or more NRTI 
mutations, and 41% to 44% with 3 or more mutations associ-
ated with darunavir resistance. De novo enfuvirtide was used 
in approximately one quarter of patients.
The primary endpoint in the DUET studies was the propor-
tion of patients achieving viral suppression 50 copies/mL, 
based on time to loss of virologic response using intention-to-
treat analyses (ITT-TLOVR). At 24 weeks, pooled analyses 
showed that significantly more patients in the etravirine arm 
compared to placebo achieved viral RNA  50 copies/mL 
(59% versus 41%, respectively, P  0.001);24 these findings 
were similar to the results observed in the individual DUET 
studies.22,23 Pooled results at 48 and 96 weeks confirmed 
the published 24-week results, with 61% etravirine patients 
and 40% placebo patients maintaining viral suppression 
to 50 copies/mL, P  0.0001 at 48 weeks,25 and 57% 
etravirine patients and 36% placebo patients remaining unde-
tectable at 96 weeks (P  0.0001).26 Virologic suppression 
was stable in the pooled cohort from week 48 to week 96; 
83% of subjects who achieved viral load 50 copies/mL at 
24 weeks, and 91% of subjects with viral load 50 copies/mL 
at 48 weeks remained undetectable at 96 weeks.26
Baseline viral load, CD4 count, enfuvirtide use and the 
number of active antiretrovirals in the background regimen 
were significant predictors for virologic response at 48 weeks 
for both treatment and placebo groups in pooled analysis.27 
Even in subjects with no active drugs in the background 
regimen, a significantly higher virologic response rate was 
seen at 96 weeks in those treated with etravirine versus 
placebo (46% versus 6%, P  0.0001).26 Based on gen-
eralized additive modeling analysis, etravirine AUC or 
Ctrough was not significantly associated with achieving viral 
load 50 copies/mL at week 48.28
In terms of immunological response, a greater increase 
in CD4 count from baseline was observed in etravirine 
subjects compared to placebo, with a mean increases of 
86 versus 67 cells/mm3 respectively based on pooled analysis 
at 24 weeks.24 This effect was maintained at 48 weeks, with 
pooled results of mean 98 and 73 cells/mm3 increases in 
treatment versus placebo arms, respectively (P  0.0006).25
At 48 weeks, patients treated with etravirine experienced 
a significantly lower rate of AIDS-defining events (ADE) or 
death compared to patients on placebo (5.8% versus 9.8% 
respectively, P = 0.0408). Time to first confirmed ADE/death 
was significantly shorter in the placebo group versus etravirine 
group (P = 0.0108). Etravirine patients also experienced 
fewer cumulative hospital days compared to placebo 
patients over 48 weeks (1702 versus 2747, P = 0.0195).29 
By 96 weeks, the differences between the etravirine versus 
placebo arms had narrowed, but remained slightly more 
favorable in the etravirine group. The overall proportion of 
patients with any clinical endpoint by 96 weeks was 8.2% in 
the etravirine arm and 10.9% in the placebo arm (P = 0.27). 
With respect to confirmed or probable AIDS-defining illness, 
rates of 5.8% and 9.4% were observed in the etravirine and 
placebo recipients, respectively (P = 0.06). The time to 
first confirmed or probable AIDS-defining illness or death 
remained significantly longer in the etravirine versus placebo 
group (P = 0.05). Subjects in the etravirine arm had fewer 
cumulative days in hospital compared to the placebo group 
(2737 versus 3453 days), although this difference was no 
longer statistically significant, with a P-value of 0.25.30
Results from a phase II noncomparative study of etravirine 
with raltegravir and darunavir/ritonavir (TRIO trial) in 103 
treatment-experienced subjects with multi-drug resistant 
virus suggested promising efficacy. At baseline, median viral 
load was 4.2 log10 copies/mL, CD4 was 255 cells/mm3, and 
median number of mutations was 4 for protease inhibitors 
(2 for darunavir), 1 for NNRTIs and 6 for NRTIs. At 24 weeks 
follow-up, 90% of patients achieved the primary endpoint 
of HIV viral suppression to less than 50 copies/mL, and 
a median increase of 99 CD4 cells/mm3 from baseline 
was observed.31 Between weeks 24 and 48, 4 patients Therapeutics and Clinical Risk Management 2010:6 53
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experienced virologic failure, resulting in 86% virologic 
suppression rate at 48 weeks with a median CD4 increase 
of 108 cells/mm3.32
Similarly, in a retrospective study involving 53 treatment-
experienced patients with multi-class resistance who were 
co-enrolled in etravirine and raltegravir expanded access 
programs, 94% achieved undetectable HIV viral load 
at 24 weeks, with a median CD4 increase of 86 cells/mm3. 81% 
of this cohort also received de novo darunavir/ritonavir as part 
of their new background regimen.33 Almost identical results 
were observed in a Spanish cohort of 32 consecutive heavily 
treatment experienced HIV-positive patients who were treated 
with etravirine, raltegravir and darunavir 600 mg/100 mg 
twice daily. At baseline, the median age was 44 years, CD4 
261 cells/mm3 and HIV RNA 4.2 log10 copies/mL. Median 
time on antiretroviral therapy was 13 years, with an average 
of nine prior HAART regimens; 50% were enfuvirtide-
experienced, and 44% had been on prior tipranavir therapy. 
All patients had triple-class resistance; 3 had etravirine 
resistance mutations. All subjects were darunavir-naïve, 
and had a median of one darunavir-resistance mutation. 
At week 24, 94% of subjects achieved undetectable viral load, 
with a median CD4 increase of 103 cells/mm3.34
The global etravirine early access program (TMC125-C214) 
involved triple-class antiretroviral experienced patients who 
had received at least two prior PI-containing regimens. 
At screening, patients with undetectable viral loads were 
permitted to switch from enfuvirtide to etravirine for reasons 
of intolerance or simplification; optimization of other 
components of the background regimen was also allowed at 
this time. Follow-up was reported for 37 patients, 36 (97%) of 
whom used etravirine in combination with darunavir/ritonavir; 
62% also used raltegravir, 16% used maraviroc, and 89% 
used concomitant NRTIs. At 24 weeks, 35 (95%) of subjects 
maintained viral suppression 50 copies/mL; one subject had 
a viral load of 50 copies/mL, and the other had missing data 
at week 24, but viral load 50 copies/mL at week 12.35
The GRACE study was a multi-center, 48-week, 
open-label phase IIIb study assessing the efficacy and 
safety of darunavir/ritonavir plus optimized background 
regimen in treatment-experienced patients. This study 
was specifically designed to enroll a high proportion of 
treatment-experienced women and people of color. A pre-
planned subgroup analysis evaluated virologic response and 
safety in subjects who received etravirine as a component of 
their optimized background. Of 429 subjects who enrolled 
in GRACE, 207 received at least one dose of etravirine. 
Of these, 119 (57%) were female, of whom 70.6% were 
black and 16% were Hispanic. Overall baseline viral load 
was 4.6 log10 copies/mL, CD4 187 cells/mm3, and median 
fold-change in etravirine susceptibility was 1.4. At 48 weeks, 
the overall response was 49.5% in the intention to treat, 
time-to-loss of virologic response (ITT-TLOVR) and 76.4% 
intention-to-treat censored group who discontinued for rea-
sons other than virologic failure. Similar virologic response 
rates were observed for women and men in this subgroup. In 
a post hoc multivariate analysis of all GRACE participants, 
inclusion of etravirine was one of the factors significantly 
predictive of virologic response, with an odds ratio of 1.56, 
P = 0.0424.36
Pediatric experience with etravirine is extremely 
limited. One case reported the use of darunavir/ritonavir 
and etravirine in a premature male infant vertically infected 
with multi-drug resistant HIV-1. The child was delivered 
at 33 weeks by emergency cesarean section to a treatment-
experienced mother with a viral load of 4.4 log10 copies/mL 
and CD4 76 cells/mm3 at delivery; genotypic testing revealed 
the presence of 11 mutations at the reverse transcriptase 
site (D67N, T69N, K70R, A98S, K103N, V118I, V179E, 
M184V, Y188L, T215F, K219E) as well as the protease 
site (L10I, K20M, M36I, M46I, L63P, A71V, G73S, V77I, 
I84V, L90M, I93L). At birth, the patient’s viral load was 
5.92 log10 copies/mL, and genotypic testing showed identical 
resistance mutations as the mother. During the first year and a 
half of life, the patient was sequentially treated with numerous 
RTIs, lopinavir/ritonavir and enfuvirtide, but his clinical 
condition deteriorated rapidly. At 21 months of age, his CD4 
was 10 cells/mm3, viral load was 5.80 log10 copies/mL, and 
genotypic testing showed the same resistance mutations at 
birth plus gp41-associated mutations. At 24 months of age, 
the patient began darunavir 150 mg/ritonavir 20 mg twice 
daily plus etravirine 50 mg twice daily (increased to 100 mg 
twice daily after 2 months) through compassionate access 
plus lamivudine 4 mg/kg twice daily. Pharmacokinetic 
assessment at day 70 showed darunavir and etravirine trough 
plasma concentrations of 5270 and 650 ng/mL, respectively, 
which are within reported therapeutic ranges. Over the 
following 15 months, the antiretroviral regimen was well 
tolerated, the patient’s condition significantly improved with 
normalization of numerous laboratory parameters, and an 
undetectable viral load was achieved and maintained from 
12 months onwards.37
In France, 12 heavily pretreated, perinatally infected 
adolescents received the combination of darunavir/
ritonavir, etravirine and raltegravir through a compassionate 
program between October 2006 and December 2007. Therapeutics and Clinical Risk Management 2010:6 54
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At baseline, the median age was 15 years (range 12 to 17), 
weight 48 kg (range 28.5 to 72), CD4 124 cells/mm3 (range 
13 to 484) and viral load 5.27 log10 copies/mL (range 4.33 
to 6.1). All patients had received antiretroviral therapy for 
a median of 15 years (range 10 to 17), including a median 
of 6 NRTIs, 1 or 2 NNRTIs and 4 PIs, and 6 had previously 
received enfuvirtide. Standard adult doses of antiretrovirals 
were used in the majority of patients. After a median follow-up 
of 12 months, viral load was 400 copies/mL in 11 patients, 
with 6 having 50 copies/mL. Median CD4 count increased 
to 500 cells/mm3 by month 9. The combination was very well 
tolerated, with one patient discontinuing darunavir/ritonavir 
because of diarrhea and vomiting. No grade 3 to 4 laboratory 
parameters were noted.38
Clinical safety
In the DUET studies, pooled analysis at 96 weeks indicated 
that the incidence and severity of adverse events (AEs), serious 
AEs, laboratory abnormalities and study discontinuations 
related to AEs were comparable between the etravirine and 
placebo groups except for rash. The most common AEs 
observed in the etravirine and placebo groups were rash 
(21 versus 12, P  0.0001), diarrhea (19% versus 24%) 
and nausea (15% versus 14%).39 The incidence and severity 
of nervous system and psychiatric events, most commonly 
headache and insomnia, liver enzyme and lipid elevations 
were similar between the etravirine and placebo groups.39
Most rashes observed with etravirine were maculopular, 
of mild-moderate severity (1.3% grade 3, no grade 4 events), 
occurred at a median of 14 days after therapy initiation, and 
lasted a median 15 days. Most rashes resolved with continued 
treatment, and only 2.2% of patients discontinued etravirine 
due to rash. No cases of Stevens-Johnson syndrome, erythema 
multiforme or toxic epidermal necrolysis were reported in 
the etravirine group. There was a higher incidence of rash 
in women than men (30% versus 18%, P = 0.0365), but rash 
severity was similar. There was no relationship between rash 
and etravirine pharmacokinetic exposure,28,40 and neither CD4 
cell count nor history of NNRTI-related rash were predictive 
of rash with etravirine.40
In August 2009, the manufacturer issued a drug warning 
regarding the safety of etravirine in light of post-marketing 
reports of severe skin and hypersensitivity reactions. Cases 
included severe, potentially life-threatening and fatal reports 
of Stevens-Johnson syndrome, toxic epidermal necrolysis 
and erythema multiforme. In addition, hypersensitivity 
reactions characterized by rash, constitutional findings, and 
occasional organ dysfunction including hepatic failure were 
also reported. Prescribers are now advised to discontinue 
etravirine immediately if signs or symptoms of severe skin 
or hypersensitivity reactions develop.
Resistance
Multiple mutations have been reported to have varying 
degrees of impact on the activity of etravirine.9 The package 
insert,9 which includes a standard list of NNRTI-associated 
mutations,4 is somewhat confusing because the NVP- and 
EFV-selected mutation K103N is included in the list. Impor-
tantly, K103N, which is the most common mutations selected 
by previous exposure to either EFV or NVP, does not limit 
the activity of etravirine.9 In addition, the common EFV- and 
NVP-selected mutations G190A/S have been found not to 
have any limiting effect on the activity of etravirine.41
In general, the more other NNRTI-selected mutations 
present, the less likely is it for an etravirine-containing regi-
men to result in HIV RNA levels 50 copies/mL.22 However, 
not all mutations exert the same limiting effect on the activity 
of etravirine. The mutations L100I, K101P, Y181C/I/V, and 
M230L are the most limiting to the activity of etravirine.42 
Indeed, even one of these mutations is sufficient to reduce the 
likelihood of getting HIV RNA levels to 50 copies/mL to 
only about 50%.42 The most common of these mutations is the 
mutation Y181C. At least one of the these six very limiting 
mutations occurs about 32% of the time in persons failing 
on a nevirapine-containing regimen compared to 10% of the 
time in persons failing on an efavirenz-containing regimen.43 
Whether this difference will be shown to be clinically relevant 
as a sequencing strategy of starting with efavirenz as opposed 
to starting with nevirapine, remains to be seen.
Drug interactions
Etravirine is a substrate of CYP3A4, CYP2C9, CYP2C19 
and uridine diphosphate glucuronyltransferase (UDPGT). 
Etravirine is an inducer of CYP3A4, a weak inhibitor of 
CYP2C9 and a moderate inhibitor of CYP2C19. Etravirine 
has no clinically relevant effect on CYP1A2 or CYP2D6.44 
Etravirine may be coadministered with tenofovir, NRTIs, 
and the boosted protease inhibitors darunavir, lopinavir, 
and saquinavir, enfuvirtide and raltegravir without dosage 
adjustment. Etravirine should not be given with NNRTIs, 
unboosted PIs, as well as atazanavir/ritonavir, tipranavir/
ritonavir and fosamprenavir/ritonavir due to unfavorable 
drug interactions.
In a crossover study of healthy volunteers, no clinically 
relevant interaction was observed between etravirine 
800 mg (Phase II formulation) twice daily with food and Therapeutics and Clinical Risk Management 2010:6 55
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enteric-coated didanosine 400 mg once daily given 2 hours 
before etravirine on an empty stomach.45 Coadministration 
of tenofovir 300 mg daily plus etravirine 200 mg twice daily 
led to 19% reduction in Cmax and AUC and 18% reduction 
in Cmin of etravirine, while tenofovir pharmacokinetic 
parameters increased 15%.46 Population pharmacokinetic 
data from a subset analysis of the DUET trials suggest that 
coadministration of tenofovir was associated with a 26% 
reduction in etravirine AUC.14 In the same subset analysis, 
use of enfuvirtide had no effect on etravirine AUC.14 All of 
these effects are not considered clinically significant.
In a pharmacokinetic study involving HIV-infected 
subjects, the addition of etravirine 200 mg twice daily to 
darunavir 600 mg/ritonavir 100 mg twice daily led to approxi-
mately 30% reduction in etravirine exposures compared to 
historical controls, while darunavir pharmacokinetics were 
unchanged.47 In healthy volunteers, coadministration of 
etravirine 200 mg twice daily and lopinavir/ritonavir tablets 
400/100 mg twice daily for 8 days resulted in reductions 
of 45%, 30% and 35% in etravirine Cmin, Cmax and AUC, 
respectively, and decreases of 20%, 11% and 13% in 
lopinavir Cmin, Cmax and AUC, respectively, compared to 
each drug administered alone.48 Etravirine AUC was reduced 
33% in the presence of saquinavir 1000/ritonavir 100 mg 
twice daily.9 None of these effects are considered clinically 
meaningful.9,48
Healthy subjects who received raltegravir 400 mg twice 
daily and etravirine 200 mg twice daily for 4 days had modest 
decreases in raltegravir concentrations, with reductions of 
10%, 11% and 34% in AUC, Cmax, and C12 hours, respectively 
compared to raltegravir alone, while etravirine levels were 
not altered.49 In a cohort of 29 HIV-positive subjects receiving 
regimens including raltegravir, raltegravir/darunavir 
600 mg/ritonavir 100 mg twice daily, or raltegravir/darunavir/
ritonavir/etravirine twice daily, no differences in raltegravir 
Ctrough were noted between the groups.50
Atazanavir trough levels are reduced approximately 
40% to 50% when administered both alone and ritonavir-
boosted in the presence of etravirine. Indinavir concentrations 
are reduced 46% and saquinavir concentrations are reduced 
52% with steady-state etravirine, while etravirine exposures 
are increased 51% when co-administered with indinavir.51 
Coadministration of tipranavir/ritonavir results in a 76% 
reduction in AUC and a 82% reduction in Cmin of etravirine. 
In an open-label interaction trial of HIV-infected subjects on 
stable fosamprenavir 700 mg plus ritonavir 100 mg twice 
daily, addition of etravirine 800 mg (Phase II formulation) 
bid for 14 days led to increases of 69%, 62% and 77% in 
AUC, Cmax and Cmin of amprenavir, respectively, compared 
to boosted fosamprenavir alone. Etravirine parameters were 
similar to historical controls.52 Etravirine should not be 
used in combination with atazanavir, indinavir, saquinavir, 
tipranavir, fosamprenavir due to these interactions.
Administration of single-dose etravirine 900 mg in the 
presence of steady-state EFV 600 mg daily or NVP 200 mg 
twice daily resulted in significant reductions in etravirine 
exposure. Etravirine AUC was reduced 41% and 55% 
and Cmax was reduced 18% and 36% with EFV and NVP, 
respectively.51 Consequently, etravirine should not be used 
in combination with either EFV or NVP.
In a healthy volunteer study, etravirine was administered 
400 mg daily or 200 mg twice daily for 14 days at baseline 
and then again after 14 days of EFV treatment to assess 
for any continued effects of EFV enzyme induction on 
etravirine metabolism. Steady-state etravirine parameters 
were significantly reduced after EFV intake in both the 
once- and twice-daily dosing arms; etravirine AUC was 
reduced 28% to 29%, Cmax was reduced 28% to 29%, and 
Ctrough was reduced by 33% to 37%. These changes are likely 
not clinically significant as all subjects had etravirine levels 
well above the protein binding-adjusted EC50 of 4 ng/mL 
and concentrations were comparable to those observed in 
clinical trials where etravirine was co-administered with 
darunavir/ritonavir. Therefore, the authors suggest that 
switching from EFV to etravirine once or twice daily may 
be done without dose adjustment.53
In a healthy volunteer study, steady state etravirine 
concentrations were increased by 75%–109% in the presence 
of fluconazole 200 mg daily for 9 days. This combination 
was well tolerated; a post-hoc analysis of adverse events 
in DUET-1 and DUET-2 over 96 weeks in patients with or 
without concomitant fluconazole showed no difference in 
safety parameters.54 In healthy volunteers, coadministration 
of etravirine 200 mg twice daily plus voriconazole 200 mg 
twice daily for 9 days resulted in increases of 52%, 26% and 
36% of etravirine Cmin, Cmax and AUC, respectively, while vori-
conazole Cmin and AUC increased 23% and 14% respectively 
(only in subjects who were not carriers of the CYP2C19*2 
allele) compared to either drug administered alone. In this 
study, the combination was well tolerated.54 However, in 
clinical practice, a reduction in dosage of both agents may 
be required, and therapeutic drug monitoring of both agents 
should be considered if available. Etravirine may be coad-
ministered with methadone and oral contraceptives without 
dosage modification.9,55 A summary of drugs that should not 
be co-administered with etravirine is provided in Table 1.Therapeutics and Clinical Risk Management 2010:6 56
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Commentary
The advent of a second-generation NNRTI represents a 
welcome advance in drug development in a well-established 
class. Etravirine is indicated for use in treatment-experienced 
patients, and offers a potent sequencing option after the 
development of resistance to first-line NNRTIs. Experience 
is limited in specific subpopulations, but preliminary data 
in pregnancy, pediatric and adolescent patients, end-stage 
liver disease and hemodialysis are promising. Etravirine 
is generally well tolerated, and has a manageable drug 
interaction profile.
Etravirine may also be considered as a suitable replace-
ment for patients who are virally suppressed on efavirenz 
or nevirapine but have developed toxicities, or women on 
efavirenz who wish to become pregnant. When switching 
a patient from efavirenz to etravirine, etravirine may be 
instituted at its regular dose without concern of enduring 
effects of efavirenz-mediated enzyme induction. While the 
manufacturer is not pursuing a once daily dosing indication 
for etravirine, pharmacokinetic data support this option, 
which offers increased flexibility when designing regimens 
for patients with adherence challenges. The current pill 
burden of etravirine is higher compared to first-line NNRTIs 
efavirenz and nevirapine (4 pills versus 1 or 2 pills daily), 
although it is comparable to the pill burden associated with 
other agents often used in treating experienced patients 
such as boosted darunavir or tipranavir (4 to 6 pills daily). 
Etravirine tablets may also be dispersed in water for patients 
who are unable to swallow tablets.
The fact that etravirine retains activity in the presence of 
the commonly EFV- and NVP-selected mutations K103N 
and G190A/S increases substantially the utility of this 
antiretroviral. However, multiple NNRTI-selected muta-
tions, often interacting in complex and difficult to predict 
ways, will limit the activity of etravirine by varying amounts. 
Consequently, a reliable resistance test, such as either the 
PhenosenseTM assay or the virco®TYPE HIV-1 assay56 should 
be obtained prior to the initiation of therapy with etravirine, 
especially in situations in which genotypic resistance testing 
has demonstrated multiple NNRTI-selected mutations.
Summary
Etravirine is a second generation NNRTI with the advantages 
of in vitro potency against many strains of virus resistant to 
efavirenz and nevirapine, as well as a higher genetic barrier 
to resistance. In randomized, controlled trials, twice daily 
etravirine (combined with darunavir/ritonavir) demonstrated 
efficacy compared to placebo in treatment-experienced 
populations out to 96 weeks follow-up. The main toxicity 
is mild to moderate self-limiting rash, although severe 
and sometimes fatal hypersensitivity reactions have been 
reported. Etravirine is a substrate and inducer of CYP3A4, 
with a similar interaction profile as other NNRTIs. Etravirine 
is indicated for use in treatment-experienced patients, and 
offers a potent sequencing option after the development of 
resistance to first-line NNRTIs.
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